Edwards Lifesciences Corporation Stock News

U.S. heart valve maker Edwards Lifesciences has been hit with an EU antitrust complaint by Indian rival Meril including for allegedly anti-competitive practices related to patents, a move that could b

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the

Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.

The heavy selling pressure might have exhausted for Edwards Lifesciences (EW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Explore how Edwards Lifesciences' (EW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.

Edwards Lifesciences Corporation (NYSE:EW ) Q1 2024 Earnings Conference Call April 25, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Daveen

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with W

Edwards Lifesciences (EW) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.62 per share a year ago.

Edwards Lifesciences Corp on Thursday reported upbeat first-quarter profit due to strong demand for its artificial heart valves and other medical devices.

Edwards Lifesciences stock was muted late Thursday after the company beat first-quarter calls and gave more color into a looming spinoff.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and const

Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared du